← Back to Search

Reading Intervention for Autism (BrainREAD Trial)

Phase < 1
Recruiting
Research Sponsored by University of Alabama, Tuscaloosa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10-12 weeks
Awards & highlights

BrainREAD Trial Summary

This trial will test the impact of a reading intervention program on children with ASD to see if it changes the neurobiological mechanisms underlying reading comprehension deficits.

Who is the study for?
This trial is for children aged 7-13 with Autism Spectrum Disorder (ASD) who have average decoding skills but below-average reading comprehension. They must not be on certain medications like antipsychotics, anti-epileptics, or stimulants before testing and should have an IQ over 70. Neurotypical kids without ASD can join if they also struggle with reading comprehension.Check my eligibility
What is being tested?
The study tests a reading program called Visualizing and Verbalizing to see if it improves brain connectivity related to reading in kids with ASD. It compares the effects of this intervention between children with ASD and neurotypical children who both face similar challenges in understanding what they read.See study design
What are the potential side effects?
Since this trial involves a non-medical intervention focused on education, there are no direct medical side effects expected from the Visualizing and Verbalizing program itself.

BrainREAD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10-12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10-12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in reading comprehension
Brain
Secondary outcome measures
Behavior Therapy

BrainREAD Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ASD-EXP and NT-EXPExperimental Treatment1 Intervention
Autistic children and Neurotypical children who receive intervention between pre and post testing
Group II: ASD-WLC and NTActive Control1 Intervention
Autistic children who receive intervention only after their pre and post testing and Neurotypical children who do not receive any intervention

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamOTHER
1,594 Previous Clinical Trials
2,282,279 Total Patients Enrolled
7 Trials studying Autism Spectrum Disorder
877 Patients Enrolled for Autism Spectrum Disorder
University of Alabama, TuscaloosaLead Sponsor
45 Previous Clinical Trials
19,427 Total Patients Enrolled
3 Trials studying Autism Spectrum Disorder
575 Patients Enrolled for Autism Spectrum Disorder
~6 spots leftby Aug 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top